| 1 |
冯兴玉,蓉罗.儿童重症肺炎的诊治进展[J].临床医学进展,2024,14(10):811-816.
|
| 2 |
GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021[J]. Lancet Infect Dis, 2024, 24 (9): 974-1002.
|
| 3 |
Qian C, Chen Q, Lin W, et al. Incidence of community-acquired pneumonia among children under 5 years in Suzhou, China: a hospital-based cohort study[J]. BMJ Open, 2024, 14 (1): e078489.
|
| 4 |
Cillóniz C, Dominedò C, Garcia-Vidal C, et al. Community-acquired pneumonia as an emergency condition[J]. Curr Opin Crit Care, 2018, 24 (6): 531-539.
|
| 5 |
Bergmann JP, Kudchadkar SR. Acute respiratory failure in children-not just an acute problem[J]. Crit Care Med, 2020, 48 (8): 1237-1238.
|
| 6 |
周丽,王淼,董晓艳. 5岁及以下儿童社区获得性肺炎进展为重症肺炎的流行病学特点[J].上海医学,2023,46(7):465-470.
|
| 7 |
高娟,郑枫,张晴,等.三种常用临床指标在重症肺炎患者液体管理监测中的比较研究[J/OL].中华危重症医学杂志(电子版),2024,17(3):204-209.
|
| 8 |
中华人民共和国国家卫生健康委员会,国家中医药局.儿童社区获得性肺炎诊疗规范(2019年版)[J].中华临床感染病杂志,2019,12(1):6-13.
|
| 9 |
封志纯,祝益民,肖昕.实用儿童重症医学[M].第1版.北京:人民卫生出版社,2012.
|
| 10 |
梁学耀,葛谦益,王伟炳,等.浙江省东阳市某医院儿童肺炎患者常见呼吸道病原体的共感染分析[J].上海预防医学,2024,36(9):888-893,903.
|
| 11 |
Yang S, Lu S, Guo Y, et al. A comparative study of general and severe mycoplasma pneumoniae pneumonia in children[J]. BMC Infect Dis, 2024, 24 (1): 449.
|
| 12 |
Yang R, Xu H, Zhang Z, et al. The epidemiology of pathogens in community-acquired pneumonia among children in Southwest China before, during and after COVID-19 non-pharmaceutical interventions: a cross-sectional study[J]. Influenza Other Respir Viruses, 2024, 18 (8): e13361.
|
| 13 |
European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae Surveillance (MAPS) Study Group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions[J]. Lancet Microbe, 2024, 5 (2): e100-e101.
|
| 14 |
Lloyd CM, Saglani S. Early-life respiratory infections and developmental immunity determine lifelong lung health[J]. Nat Immunol, 2023, 24 (8): 1234-1243.
|
| 15 |
Rubin R. From "Immunity Debt" to "Immunity Theft"-how COVID-19 might be tied to recent respiratory disease surges[J]. JAMA, 2024, 331 (5): 378-381.
|
| 16 |
Li H, Li S, Yang H, et al. Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China[J]. Lancet Microbe, 2024, 5 (6): e515.
|
| 17 |
Liu B, Xu L, Ma Y, et al. Evidence of immunity gap: decline in antibodies to Mycoplasma pneumoniae during the COVID-19 pandemic[J]. J Infect, 2024, 89 (2): 106209.
|
| 18 |
Zhu Y, Luo Y, Li L, et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia[J]. Front Immunol 2023, 14: 1189647.
|
| 19 |
Lambert L, Culley FJ. Innate immunity to respiratory infection in early life[J]. Front Immunol, 2017, 8: 1570.
|
| 20 |
Spaeder MC, Milstone AM, Fackler JC. Association of bacterial pneumonia and respiratory failure in children with community-acquired influenza infection[J]. Pediatr Crit Care Med, 2011, 12 (4): e181-e183.
|
| 21 |
Ellis GT, Davidson S, Crotta S, et al. TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection[J]. EMBO Rep, 2015, 16 (9): 1203-1218.
|
| 22 |
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion[J]. Nat Rev Microbiol, 2018, 16 (6): 355-367.
|
| 23 |
杨勇晖,贺晓日,张雪菲,等.极早早产儿支气管肺发育不良的临床特征[J].中南大学学报(医学版),2023,48(10):1592-1601.
|
| 24 |
Altizer S, Dobson A, Hosseini P, et al. Seasonality and the dynamics of infectious diseases[J]. Ecol Lett, 2006, 9 (4): 467-484.
|
| 25 |
Van Woudenbergh E, Van Rooijen DM, Veldman-Wolf JJ, et al. Effect of age and season on respiratory mucosal immune marker profiles[J]. J Allergy Clin Immunol, 2024, 153 (6): 1681-1691.e12.
|